Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes Therapy
Ruboxistaurin offers addition to established diabetic nephropathy treatments
March 6th, 2006
Ruboxistaurin may be a beneficial addition to established nephropathy treatments in type 2 diabetes. According to recent research published in the journal Diabetes Care, "Ruboxistaurin selectively inhibits protein kinase C-beta and ameliorates kidney disease in animal models of diabetes. The purpose of this study was to evaluate the effects of ruboxistaurin on diabetic nephropathy in humans." K.R. Tuttle and colleagues working with the Heart Institute and Sacred Heart Medical Center in Spokane conducted "A randomized, double-blind, placebo controlled, multicenter, pilot study. [The aim was] to evaluate the effects of 32 mg/day ruboxistaurin...
Source: Obesity & Diabetes Week (2006-03-06)
|
